Goldman Sachs’s Solid Biosciences SLDB Stock Holding History

Goldman Sachs’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$999K	Buy	+100,000	New	+$758K	﹤0.01%	5214

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs's SLDB Position: Q2 2026 in Review

Goldman Sachs increased its Solid Biosciences (SLDB) stake by 71% in Q2 2026, buying an estimated $5.06M and bringing the position to 1,602,917 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #2849.

Goldman Sachs first reported a position in SLDB in Q2 2018 and has held it in 28 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Goldman Sachs held 1,602,917 shares of Solid Biosciences worth $16M as of Q2 2026.
Goldman Sachs bought 667,382 Solid Biosciences shares in Q2 2026, an estimated $5.06M.
Solid Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2849 holding.
Goldman Sachs first reported a position in Solid Biosciences in Q2 2018 and has held it in 28 quarters since.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.